Showing results (81-90 of 110) with videos related to
Sort By:
Pageof 11
Lung Cancer (Amsterdam, Netherlands)|January 14, 2021
Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patientsChengzhi Cai, Yuan Tang, Yanying Li, et al.Eclinicalmedicine|March 4, 2025
Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trialYang Xia, Panwen Tian, Mo Zhou, et al.Cancer Medicine|September 6, 2024
Impact of thoracic radiotherapy on first-line treatment outcomes in ES-SCLC patientsXiaoli Mu, Yixin Zhou, Qing Liu, et al.Journal of Thoracic Disease|September 15, 2025
Association of peripheral-blood neutrophil-to-lymphocyte ratio with Pneumocystis jirovecii pneumonia in patients with solid tumors: a case-control studyHao Zeng, Yue Gou, Chang Qi, et al.International Journal of Cancer|September 13, 2025
Clinical outcomes for neoadjuvant immunochemotherapy or chemotherapy versus concurrent chemoradiotherapy in limited-stage small-cell lung cancer: A retrospective, multi-center, real-world studyZichen Zhao, Hao Rong, Mengxia Li, et al.Future Oncology (London, England)|July 28, 2025
Molecular testing, treatment patterns, and outcomes in EGFR-mutated non-small cell lung cancer: the PISCES studyPanwen Tian, Lin Wu, Chengzhi Zhou, et al.Journal for Immunotherapy of Cancer|September 20, 2023
Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approachJie Zhao, Yayi He, Xue Yang, et al.Lung Cancer (Amsterdam, Netherlands)|August 17, 2021
Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapyPanwen Tian, Hao Zeng, Liyan Ji, et al.Journal of Genetics and Genomics = Yi Chuan Xue Bao|January 16, 2022
Characteristics of TP53 germline variants and their correlations with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patientsPanwen Tian, Xiaoyan Zhang, Sheng Yang, et al.NPJ Precision Oncology|February 5, 2026
Comparative analysis of ctDNA monitoring strategies in advanced NSCLC with MET exon 14 skipping mutations treated with ensartinibMo Zhou, Yin Zhu, Xuqi Sun, et al.Pageof 11